Core Viewpoint - The company has entered into a strategic partnership and non-exclusive technology licensing agreement with EirGenix, a global biopharmaceutical development and manufacturing enterprise, to utilize its HiCB platform for enhanced biopharmaceutical production efficiency [1][2] Group 1: Partnership and Agreement Details - The agreement grants EirGenix a non-exclusive license to the HiCB platform, which includes high-yield continuous perfusion upstream processes and integrated mixed continuous downstream purification technology [1] - The company will receive a significant upfront payment and milestone payments, along with future royalties from the commercialization of the licensed technology [1] Group 2: Technology and Benefits - The HiCB platform aims to achieve higher process efficiency, optimize process control, and ensure product consistency, significantly reducing production costs compared to traditional fed-batch production methods [1] - This collaboration is expected to enhance the affordability and accessibility of high-quality biopharmaceuticals for patients globally [2] Group 3: Future Implications - The revenue generated from this and future collaborations will be reinvested into strengthening the technology platform and advancing the research and development pipeline for next-generation innovative therapies [2]

"我们很高兴能够将HiCB平台－公司在高度一体化连续流生物工艺领域的领先成果 － 与志同道合的合 作伙伴分享，共同推动生物药生产的变革"，公司董事会主席兼首席执行官钱雪明博士表示："通过让合 作伙伴应用HiCB平台，我们可以共同推进创新生物药的可负担性和全球可及性。此次及未来合作所产 生的收益，将再度投入于技术平台的强化及研发管线的推进，致力于开发下一代、同类最佳的创新疗 法。" 格隆汇12月29日丨创胜集团-B(06628.HK)宣布，已与全球生物制药开发与生产企业，台康生技股份有限 公司("EirGenix")(TWSE: 6589)达成战略合作与非独占技术许可协议。根据协议，公司将向EirGenix授予 高度一体化连续流生物工艺制造(HiCB)平台的非独占许可，涵盖高产的连续灌流上游工艺与集成的混合 连续下游纯化技术，并提供完整的工艺文档、核心工艺技术与经验及法规支持服务。公司将获得一笔可 观的前期付款及里程碑付款，并可就许可技术的商业化应用收取未来相关的特许权使用费，这充分体现 了双方通过此次合作共同创造长期价值的一致预期。 HiCB平台旨在实现更高的工艺效率、优化工艺控制和产品一致性，与传统流加(f ...